Characteristics | PsA, n = 3161 | Control Group, n = 31,610 | p |
---|---|---|---|
Age, yrs, mean ± SD | 58.36 ± 15.42 | 58.21 ± 15.99 | NS |
Male | 1474 (46.6) | 14,740 (46.6) | NS |
Female | 1687 (53.4) | 16,870 (53.4) | NS |
Socioeconomic status† | |||
Low | 1012 (32) | 12,008 (38) | < 0.0001 |
Medium | 1320 (41.8) | 12,436 (39.3) | |
High | 798 (25.2) | 6467 (20.5) | |
Smoking | 904 (28.6) | 8742 (27.7) | NS |
Obesity, BMI > 30 | 1100 (34.8) | 8315 (26.3) | < 0.0001 |
BMI, mean ± SD | 27.5 ± 5.8 | 28.7 ± 5.9 | < 0.0001 |
Methotrexate * | 2161 (68.4) | 113 (0.4) | < 0.0001 |
Salazopyrin* | 1312 (41.5) | 67 (0.2) | < 0.0001 |
Azathioprine* | 159 (5) | 124 (0.4) | < 0.0001 |
Plaquenil* | 471 (14.9) | 179 (0.6) | < 0.0001 |
Cyclosporine* | 91 (2.9) | 59 (0.2) | < 0.0001 |
TNF-α inhibitors* | 975 (30.8) | 23 (0.1) | < 0.0001 |
Systemic steroids** | |||
None | 1059 (33.50) | 19,667 (62.22) | < 0.01 |
1–2 | 970 (30.69) | 7570 (23.95) | < 0.01 |
≥ 3 | 1132 (35.81) | 4373 (13.83) | < 0.01 |
↵† According to Clalit Health Services, correlated with Israel Central Bureau of Statistics.
↵* No. patients ever received the drug during the study period.
↵** Steroid usage was divided into 3 groups according to the no. steroid-containing preparations dispensed per year. PsA: psoriatic arthritis; BMI: body mass index; TNF-α: tumor necrosis factor-α; NS: not significant.